University of Miami Division of clinical pharmacology therapeutic rounds: Drug-induced hyperkalemia

American Journal of Therapeutics

Volumn 5, Issue 2, 1998, Pages 125-132

  Preston, Richard A ^a   Hirsh, Marc J ^a   Oster, James R ^a   Oster, Harold R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Drugs; Hyperkalemia; Potassium; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; COTRIMOXAZOLE; CYCLOSPORIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; MANNITOL; NAFAMSTAT MESILATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SUXAMETHONIUM; TACROLIMUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MALE; PNEUMOCYSTIS PNEUMONIA; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION;

EID: 0031949074     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199803000-00013     Document Type: Article

References (31)

1. Ponce SP, Jennings AE, Madias NE, et al: Drug-induced hyperkalemia. Medicine 1985;64:357-370.
2. Tannen RL: Potassium disorders. In: Fluids and Electrolytes (Eds. Koko JP, Tannen RL) WB Saunders, Philadelphia, 1995, pp 111-200.
3. Shemer J, Ezra D, Modan M, et al: Incidence of hyperkalemia in hospitalized patients. Isr J Med Sci 1983;19: 659-661.
4. Rastegar A, DeFronzo R: Disorders of potassium and acid-base metabolism in association with renal disease. In: (Diseases of the Kidney) Eds Schrier RW, Gottschalk CW. Little, Brown, Boston, 1997, pp 2451-2475.
5. Preston RA: Hyperkalemia. In: Acid Base, Fluids, and Electrolytes Made Ridiculously Simple. Medmaster, Inc, 1997, pp 85-96.
6. Pederson EB, Kornerup HJ: Relationship between plasma aldosterone concentration and plasma potassium in patients with essential hypertension during alprenolol treatment. Acta Med Scand 1976;200:263-267.
7. Bauer JH: Effects of propranolol therapy on renal function and body fluid composition. Arch Intern Med 1983; 143:927-931.
8. 2-adrenergic blockade in terminal renal failure: Absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc 1983;20: 572-576.
9. Bourke DL, Rosenberg M: Changes in total serum Ca, Na, and K with administration of succinylcholine. Anesthesiology 1978;49:361-363.
10. Smith TW, Butler VP Jr, Haber E, et al: Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. N Engl J Med 1982;307:1357-1362.
11. Papadakis MA, Wexman MP, Fraser C: Hyperkalemia complicating digoxin toxicity in a patient with renal failure. Am J Kidney Dis 1985;5:64-66.
12. Deaths associated with a purported aphrodisiac - New York City, February 1993-May 1995. MMWR Morb Mortal Wkly Rep 1995;44:853-855.
13. Manninen PH, Lam AM, Gelb AW, et al: The effect of high-dose mannitol on serum and urine electrolytes and osmolality in neurosurgical patients. Can J Anaesth 1987;34:442-446.
14. Kamel KS, Quaggin S, Scheich A, et al: Disorders of potassium homeostasis: An approach based on pathophysiology. Am J Kidney Dis 1994;24:597-613.
15. Ethier JH, Kamek KS, Magner PO, et al: The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am J Kidney Dis 1990;15:309-315.
16. Perez GO, Pelleya R, Oster JR: Renal tubular hyperkalemia. Am J Nephrol 1982;2:109-114.
17. Pelleya R, Oster JR, Perez GO: Hyporeninemic hypoaldosteronism, sodium wasting and mineralocorticoid-resistant hyperkalemia in two patients with obstructive uropathy. Am J Nephrol 1983;3:223-227.
18. Schlondorrf D: Renal complications of nonsteroidal antiinflammatory drugs. Kidney Int 1993;44:643-653.
19. Warren SE, O'Connor DT: Hyperkalemia resulting from captopril administration. JAMA 1980;2444:2551-2552.
20. Gansevoort RT, de Zeeuw D, Shahinfar S, et al: Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12(suppl 2):S37-S42.
21. Oster JR, Singer I, Fishman L: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995;98: 575-586.
22. Adu D, Turney J, Michael J: Hyperkalemia in cyclosporine-treated renal allograft recipients. Lancet 1983;2:370-372.
23. The US Multicenter FK 506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1115.
24. Asante-Korang A, Boyle GJ, Webber SA, et al: Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. J Heart Lung Transplant 1996;15:415-422.
25. Davies JP, Bentley P, Ghose RR: Aminoglutethimide-induced hyperkalemia. BJCP. 1988;43:263-264.
26. Greenberg S, Reiser IW, Chou SY, et al: Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993;119:291-295.
27. Greenberg S, Reiser IW, Chou SY: Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy. Am J Kidney Dis 1993;22:603-606.
28. Reiser IW, Chou SY, Brown MI, et al: Reversal of trimethoprim-induced antikaliuresis. Kidney Int 1996;50: 2063-2069.
29. Pennypacker LC, Mintzer J, Pitner J: Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med 1994;120:437.
30. Kleyman TR, Roberts C, Ling BN: A mechanism for pentamidine-induced hyperkalemia: Inhibition of distal nephron sodium transport. Ann Intern Med 1995;122: 103-106.
31. Muto S, Imai M, Asano Y: Mechanisms of the hyperkalemia caused by nafamostat mesilate: Effects of its two metabolites on Na and K transport properties in the rabbit cortical collecting duct. Br J Pharmacol 1994;111:173-178.